Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) on Focus After Report of Less Shorts

March 14, 2018 - By Winifred Garcia

 Vbi Vaccines Inc   Ordinary Shares (NASDAQ:VBIV) on Focus After Report of Less Shorts

The stock of Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) registered a decrease of 50.26% in short interest. VBIV’s total short interest was 423,000 shares in March as published by FINRA. Its down 50.26% from 850,400 shares, reported previously. With 96,000 shares average volume, it will take short sellers 4 days to cover their VBIV’s short positions. The short interest to Vbi Vaccines Inc – Ordinary Shares’s float is 1.1%.

The stock decreased 1.27% or $0.05 during the last trading session, reaching $3.89. About 65,576 shares traded. VBI Vaccines Inc. (NASDAQ:VBIV) has risen 7.87% since March 14, 2017 and is uptrending. It has underperformed by 8.83% the S&P500.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $156.49 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

VBI Vaccines Inc. (NASDAQ:VBIV) Ratings Coverage

Among 4 analysts covering VBI Vaccines (NASDAQ:VBIV), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. VBI Vaccines had 6 analyst reports since July 26, 2016 according to SRatingsIntel. The firm has “Buy” rating by BMO Capital Markets given on Wednesday, November 15. The stock has “Buy” rating by Canaccord Genuity on Wednesday, November 1. The stock has “Buy” rating by Ladenburg Thalmann on Tuesday, July 26. As per Monday, October 10, the company rating was initiated by Laidlaw.

More notable recent VBI Vaccines Inc. (NASDAQ:VBIV) news were published by: Benzinga.com which released: “Exclusive: VBI Vaccines CEO Talks Pipeline, Investor Backing, Hep. B Vaccine …” on April 03, 2017, also Benzinga.com with their article: “Meet VBI Vaccines, The Biotech Up 100% In 2017” published on March 07, 2017, Quotes.Wsj.com published: “VBI Vaccines Inc. VBIV (US: Nasdaq)” on July 29, 2014. More interesting news about VBI Vaccines Inc. (NASDAQ:VBIV) were released by: Globenewswire.com and their article: “VBI Vaccines Announces Proposed Concurrent Public Offering and Registered …” published on October 25, 2017 as well as Benzinga.com‘s news article titled: “VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.